Clinical trials: Alopecia Totalis/Universalis
Alopecia Areata
PF-06651600 for the Treatment of Alopecia Areata
This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss.
- Trial name
- ALLEGRO-2b/3 (NCT03732807)
- Testing
- PF-06651600 Induction Dose, PF-06651600 Maintenance Dose #1, PF-06651600 Maintenance Dose #2
- Where
- 155 sites in United States, Argentina and 16 more
- Volunteers
- 718 people
- Sponsor
- Pfizer
Alopecia Areata
Long-Term PF-06651600 for the Treatment of Alopecia Areata
This is a global Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have alopecia areata.
- Trial name
- ALLEGRO-LT (NCT04006457)
- Testing
- PF-06651600, Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine, Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine
- Where
- 144 sites in United States, Argentina and 15 more
- Volunteers
- 1,057 people
- Sponsor
- Pfizer
Alopecia Totalis, Alopecia Universalis
Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata
Systemic Pulse Glucocorticoids have been shown to be effective in widespread Alopecia areata but not the totalis, universalis or ophiasic type.
- Conditions
- Alopecia Totalis, Alopecia Universalis, Ophiasic Alopecia
- Trial name
- NCT01167946
- Testing
- methylprednisolone sodium succinate
- Where
- Saudi Arabia
- Volunteers
- 42 people
- Sponsor
- King Saud University
Alopecia Areata, Alopecia Totalis
Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.
To determine the efficacy of oral Tofacitinib in the treatment of moderate to severe alopecia areata, totalis and universalis at tertiary care hospital of Karachi, Pakistan.
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis
- Trial name
- NCT06278402
- Testing
- Tofacitinib
- Where
- Pakistan
- Volunteers
- 30 people
- Sponsor
- Jinnah Hospital
Alopecia Areata, Alopecia Totalis
The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic
The study series consists of three studies with the aim to assess the incidence, prevalence, risk factors, comorbidities and management of patients with alopecia areata in Czech Republic based on the patients and registry of a…
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Alopecia Areata (& Ophiasis)
- Trial name
- NCT05098600
- Testing
- Exposure of interest
- Where
- Czechia
- Volunteers
- 123 people
- Sponsor
- Faculty Hospital Kralovske Vinohrady
Alopecia Areata, Alopecia Totalis
Systemic Treatments for Alopecia Areata Registry
A multicenter prospective registry (STA2R) is conducted to assess systemic treatments for alopecia areata, focusing on effectiveness, safety, and long-term outcomes.
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Hair Loss
- Trial name
- STA2R (NCT06283316)
- Where
- Netherlands
- Volunteers
- 10,000 people
- Sponsor
- Erasmus Medical Center
Alopecia Areata(AA), Alopecia Areata (AA)
Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care Effectiveness Study
Rationale: Since the introduction of Janus kinase (JAK) inhibitors, there has been a significant advancement in the treatment of pediatric alopecia areata.
- Conditions
- Alopecia Areata(AA), Alopecia Areata (AA), Alopecia Totalis/Universalis, Alopecia Universalis (AU)
- Trial name
- COMPARE (NCT07381556)
- Testing
- Methotrexate, Cyclosporin (CSA)
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Erasmus Medical Center
Alopecia Areata, Alopecia Totalis
Alopecia Areata Registry
Alopecia areata is the loss of hair in patches that can proceed to loss of all hair (alopecia totalis or universalis). The purpose of the registry is to collect patient information and blood samples from people with alopecia…
- Conditions
- Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Autoimmune Hair Loss
- Trial name
- NAAR (NCT00069589)
- Where
- 5 sites in United States
- Volunteers
- 3,100 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Alopecia Areata
Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)
Provide pre-approval single patient Expanded Access (compassionate use) of Ritlecitinib for patients.
- Trial name
- NCT05522556
- Testing
- Ritlecitinib
- Sponsor
- Pfizer
Alopecia Areata
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of alopecia areata.
- Trial name
- ALLEGRO-100 (NCT06873945)
- Testing
- Ritlecitinib 100 mg, Ritlecitinib 50 mg
- Where
- 148 sites in United States, Canada and 9 more
- Volunteers
- 674 people
- Sponsor
- Pfizer